Key result
New oral anticoagulants, including direct anti-Xa and antithrombin agents, are in various phases of clinical development and show promising efficacy and safety for preventing venous thromboembolism.
New oral anticoagulants offer a promising, simplified alternative to traditional anticoagulants for VTE prophylaxis.
Answers are grounded in this paper and cite their sources.
Early data on new oral anticoagulants for VTE prevention are hypothesis-generating; large RCTs needed before practice consideration.
New anticoagulants for the prevention of venous thromboembolism Cecilia Becattini, Alessandra Lignani, Giancarlo AgnelliInternal and Cardiovascular Medicine and Stroke Unit, University of Perugia, ItalyAbstract: Anticoagulant drugs have an essential role in the prevention and treatment of thromboembolic diseases. Currently available anticoagulants substantially reduce the incidence of thromboembolic events in a number of clinical conditions. However, these agents have limitations that strengthen the case for the development of new anticoagulants. An ideal anticoagulant should be at least as effective as those currently in use, as well as safe, simple to use, and widely applicable. The majority of new anticoagulants currently under investigation are small molecules with a selective and direct anti-Xa or antithrombin action, allowing oral administration in fixed doses. These new agents are in different phases of clinical development. The anti-Xa agent rivaroxaban and the antithrombin agent dabigatran are already available for the prophylaxis of venous thromboembolism in some countries. Apixaban is in an advanced phase of clinical development and several anti-Xa agents are currently approaching phase III clinical trials. Promising results in terms of efficacy and safety profiles have been obtained with these agents in different clinical conditions. Differences in pharmacokinetics and pharmacodynamics could offer the potential for individualized anticoagulant therapies in the near future.
No takes yet. Share an insight, caveat, or question.
Becattini et al. (2010) conducted a review in Venous thromboembolism. New anticoagulants (direct anti-Xa and antithrombin agents) was evaluated. New oral anticoagulants, including direct anti-Xa and antithrombin agents, are in various phases of clinical development and show promising efficacy and safety for preventing venous thromboembolism.
Synapse has enriched 10 related papers. Consider them for comparative context: